ALK-Abelló — Major Shareholding Notification 2011

Dec 15, 2011

To NASDAQ OMX Copenhagen A/S

Company release No 26/2011

Hørsholm 15 December 2011	Lundbeckfond Invest A/S increases its ownership in ALK
Page 1/1	Pursuant to section 29 of the Danish Securities Trading Act, ALK has received notification from Lundbeckfond Invest A/S that Lundbeckfond Invest A/S, Hellerup, Denmark, has increased its ownership in ALK-Abelló A/S.

Lundbeckfond Invest A/S now owns 39.40% of the company share capital equivalent to 920,720 A shares and 3,069,680 B shares, and 66.67% of the votes.

ALK-Abelló A/S

Jens Bager President and CEO

For further information please contact:

Jens Bager, President and CEO, tel. +45 4574 7576

About ALK

ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy – a unique treatment of the underlying cause of allergy. The company has approximately 1,750 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii Pharmaceutical Co. Ltd. to commercialise allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hørsholm, Denmark, and listed on the NASDAQ OMX Copenhagen A/S. Find more information at www.alk-abello.com.

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143